Advanced Glycation and ROS: a link between diabetes and heart failure.
Despite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches are also discussed.
Rojas
Armando
A
School of Medicine, Health Sciences Faculty, Catholic University of Maule, Talca, Chile. arojasr@ucm.cl
Mercadal
Enrique
E
Figueroa
Hector
H
Morales
Miguel A
MA
D000818:Animals; D006332:Cardiomegaly / Q000473:pathology; D003324:Coronary Artery Disease / Q000473:pathology; D048909:Diabetes Complications / Q000378:metabolism; D003920:Diabetes Mellitus / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000502:physiology; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006321:Heart / Q000502:physiology; D006333:Heart Failure / Q000150:complications / Q000378:metabolism*; D006801:Humans; D032383:Myocytes, Cardiac / Q000473:pathology; D017382:Reactive Oxygen Species / Q000378:metabolism*; D020257:Ventricular Remodeling / Q000502:physiology
D017127:Glycation End Products, Advanced; D017382:Reactive Oxygen Species